Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Liminal BioSciences Inc logo
    LMNL

    Liminal BioSciences Inc

    MaveScore 15 Low model confidence
    Last Price US$8.50 As of Updating
    Market Cap US$263.8m Company size context
    7D Performance 0.35% Past 7 days
    1Y Performance -99.93% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2022

    1263 days old

    Market price date

    Updating

    Refreshing

    Coverage

    8/16

    8 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 15 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    8/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    14/35 Weak

    Financial Strength

    Financial strength needs live profitability and cash-flow fields.

    0/25 Needs Data

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    0/15 Weak

    Momentum

    Momentum needs recent 3-month or 6-month price-change data.

    0/15 Needs Data

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    1/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, latest price, 3-month price change, 6-month price change.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Liminal BioSciences Inc Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

    Liminal BioSciences Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Liminal BioSciences Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    Liminal BioSciences Inc Competitors

    Liminal BioSciences Inc operates in the Biotechnology & Medical Research industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Liminal BioSciences Inc

    US$8.50

    US$263.8m

    0.35%

    -99.93%